Voya Investment Management LLC Sells 129,093 Shares of BioCryst Pharmaceuticals, Inc. $BCRX

Key Points

• Voya Investment Management LLC reduced its stake in BioCryst Pharmaceuticals by 20.6%, selling 129,093 shares and retaining approximately 0.24% of the company.
• BioCryst Pharmaceuticals reported $0.15 EPS for the last quarter, exceeding analysts' expectations of $0.03 EPS, with revenue up 49.5% year-over-year.
• Analysts maintain a predominantly positive outlook on BioCryst Pharmaceuticals, with an average price target of $16.70 and a consensus rating of "Moderate Buy."

Voya Investment Management LLC reduced its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 20.6% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 496,812 shares of the biotechnology company's stock after selling 129,093 shares during the period. Voya Investment Management LLC owned about 0.24% of BioCryst Pharmaceuticals worth $3,726,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of BCRX. Man Group plc increased its holdings in shares of BioCryst Pharmaceuticals by 46.3% in the 4th quarter. Man Group plc now owns 89,954 shares of the biotechnology company's stock worth $676,000 after purchasing an additional 28,481 shares in the last quarter. Quantinno Capital Management LP lifted its stake in BioCryst Pharmaceuticals by 38.2% during the 4th quarter. Quantinno Capital Management LP now owns 14,828 shares of the biotechnology company's stock valued at $112,000 after acquiring an additional 4,097 shares during the period. ProShare Advisors LLC raised its holdings in shares of BioCryst Pharmaceuticals by 32.6% during the fourth quarter. ProShare Advisors LLC now owns 68,004 shares of the biotechnology company's stock valued at $511,000 after purchasing an additional 16,732 shares during the last quarter. Two Sigma Investments LP raised its holdings in shares of BioCryst Pharmaceuticals by 0.8% during the fourth quarter. Two Sigma Investments LP now owns 1,774,214 shares of the biotechnology company's stock valued at $13,342,000 after purchasing an additional 13,406 shares during the last quarter. Finally, Woodline Partners LP purchased a new position in shares of BioCryst Pharmaceuticals during the fourth quarter valued at approximately $3,385,000. Institutional investors own 85.88% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have commented on BCRX. Wall Street Zen raised shares of BioCryst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Saturday, July 26th. Bank of America raised their price target on BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the stock a "buy" rating in a research note on Tuesday, July 1st. Wedbush increased their target price on BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the company an "outperform" rating in a report on Monday, June 30th. Needham & Company LLC reaffirmed a "buy" rating and set a $17.00 price target on shares of BioCryst Pharmaceuticals in a research report on Monday, August 4th. Finally, Royal Bank Of Canada reaffirmed an "outperform" rating and set a $13.00 price target on shares of BioCryst Pharmaceuticals in a research report on Monday, June 30th. Nine research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $16.70.

BioCryst Pharmaceuticals Price Performance

Shares of NASDAQ:BCRX traded down $0.02 during trading on Tuesday, reaching $7.90. 152,306 shares of the company were exchanged, compared to its average volume of 3,643,265. The firm has a market capitalization of $1.66 billion, a PE ratio of -43.86, a P/E/G ratio of 1.55 and a beta of 1.13. The business's fifty day simple moving average is $8.30 and its 200-day simple moving average is $8.72. BioCryst Pharmaceuticals, Inc. has a 12-month low of $6.01 and a 12-month high of $11.31.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last announced its quarterly earnings data on Monday, August 4th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.03 by $0.12. The firm had revenue of $163.35 million during the quarter, compared to the consensus estimate of $149.59 million. During the same period last year, the company earned ($0.06) EPS. The firm's revenue for the quarter was up 49.5% compared to the same quarter last year. On average, sell-side analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current fiscal year.

Insider Buying and Selling

In other BioCryst Pharmaceuticals news, Director Theresa Heggie sold 70,000 shares of the firm's stock in a transaction dated Wednesday, August 13th. The shares were sold at an average price of $8.51, for a total transaction of $595,700.00. Following the transaction, the director owned 65,352 shares of the company's stock, valued at approximately $556,145.52. This trade represents a 51.72% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 5.10% of the company's stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.